RxDoctor Payments Data

Ted Lin, MD

Interventional Pain Medicine · Sugar Land, TXNPI 1730346966

Payments from drug & device makers

$6,165in general payments, 2019–2025

Across 188 payments — averaging $32.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Saluda Medical Americas, Inc.$337
  • Nevro Corp.$263
  • Abbott$251
  • Nalu Medical, Inc.$188
  • Boston Scientific$176
  • plus $601 from 16 others

What the payments were for

  • Travel & lodging$68511%
  • Food & beverage$5,48089%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,165 in reported general payments places this provider in the 45th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$223,119
Medicare patients
341
Services billed
2,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl20$15,289
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen347$8,066
Buprenorphine37$8,053
Gabapentin205$3,368
Pregabalin111$2,044
Methocarbamol105$1,729
Tizanidine Hcl84$1,608
Celecoxib51$1,381
Baclofen74$1,344
Acetaminophen-CodeineAcetaminophen With Codeine86$1,291
Tramadol Hcl102$947
Naloxone Hcl13$822
Cyclobenzaprine Hcl53$820
Oxycodone Hcl19$536
Duloxetine Hcl32$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$17$15,28920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →